aberrations and match sufficient to tolerate FCR therapy, should be superior candidates for that latter, with the gain currently being this treatment method could be completed in six months when ibrutinib has to be taken indefinitely.That notwithstanding, both equally subtypes of MBL can have ‘CLL-unique’ genomic aberrations including cytogenet